目的 探討丹莪婦康煎膏聯(lián)合醋酸亮丙瑞林微球治療復(fù)發(fā)性子宮內(nèi)膜異位癥的臨床療效。方法 選取2016年3月-2017年9月在首都醫(yī)科大學(xué)附屬北京婦產(chǎn)醫(yī)院治療的復(fù)發(fā)性子宮內(nèi)膜異位癥患者78例，根據(jù)用藥差別分為對(duì)照組（39例）和治療組（39例）。對(duì)照組患者腹部皮下注射注射用醋酸亮丙瑞林緩釋微球，月經(jīng)周期第1天給藥，3.75 mg/次，1次/4周；治療組在對(duì)照組基礎(chǔ)上于月經(jīng)開始前10 d口服丹莪婦康煎膏，15 g/次，2次/d。兩組患者均經(jīng)過(guò)12周治療。評(píng)價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組子宮內(nèi)膜厚度、Kupperman和視覺(jué)模擬評(píng)分（VAS）及性激素水平和血清學(xué)指標(biāo)。結(jié)果 治療后，對(duì)照組臨床有效率為79.50%，顯著低于治療組的94.87%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者子宮內(nèi)膜厚度顯著縮?。?i>P<0.05），Kupperman評(píng)分和VAS明顯降低（P<0.05）；且治療組子宮內(nèi)膜厚度、Kupperman和VAS評(píng)分均明顯小于對(duì)照組（P<0.05）。治療后，兩組患者血清促卵泡成熟激素（FSH）、黃體生成激素（LH）、雌二醇（E2）水平明顯下降（P<0.05）；且治療組患者性激素水平明顯低于對(duì)照組（P<0.05）。治療后，兩組血清CA125、抗子宮內(nèi)膜抗體（EMAb）水平均顯著降低（P<0.05）；且治療組CA125和EMAb水平明顯低于對(duì)照組（P<0.05）。結(jié)論 丹莪婦康煎膏聯(lián)合醋酸亮丙瑞林微球治療復(fù)發(fā)性子宮內(nèi)膜異位癥可有效改善患者絕經(jīng)癥狀和疼痛，調(diào)節(jié)機(jī)體性激素水平，降低血清CA125、EMAb含量。

Objective To investigate the clinical efficacy of Dan'e Fukang Soft Extracts combined with leuprolide acetate microspheres in treatment of recurrent endometriosis. Methods Patients (78 cases) with recurrent endometriosis in Beijing Obstetrics and Gynecology Hospital, Capital Medical University from March 2016 to September 2017 were divided into control (39 cases) and treatment (39 cases) group based on different treatment. Patients in the control group were abdominal subcutaneous injection administered with Leuprorelin Acetate Microspheres Sustained Release for injection on the first day of menstruation, 3.75 mg/time, once every 4 weeks. Patients in the treatment group were po administered with Dan'e Fukang Soft Extracts on the basis of the control group 10 d before menstruation, 15 g/time, twice daily. Patients in two groups were treated for 12 weeks. After treatment, the clincial efficacies were evaluated, and the endometrial thickness, Kupperman and VAS scores, the sex hormone levels, the serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 79.50%, which was significantly lower than 94.87% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the thickness of the endometrium in two groups was significantly reduced (P<0.05), Kupperman and VAS was significantly decreased (P<0.05). And the thickness of the endometrium, Kupperman and VAS in the treatment group after treatment was significantly lower than that in the control group (P<0.05). After treatment, the FSH, LH and E2 levels in two groups were significantly decreased (P<0.05), and the sex hormone levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). After treatment, the CA125 and EMAb levels in two groups were significantly decreased (P<0.05), and the CA125 and EMAb levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). Conclusion Dan'e Fukang Soft Extracts combined with leuprolide acetate microspheres in treatment of recurrent endometriosis can effectively improve the menopausal symptoms and pain, sex hormone and decrease the CA125 and EMAb levels.